Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Completed · Phase 1/Phase 2

Conditions studied: Mantle-Cell Lymphoma

In brief

Defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogenic signal is present. Obatoclax is designed to restore apoptosis through inhibition of the Bcl-2 family of proteins, thereby reinstating the natural process of cell death that is often inhibited in cancer cells.

Key facts

Study ID

NCT00407303

Run by

Gemin X

People needed

24

Starts

2006-10-01

Expected to finish

2009-11-01

Last updated by the study team

2016-07-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Pathological confirmation of Mantle Cell Lymphoma (ML)
• Must have documented relapse or progression following 1 or 2 prior lines of antineoplastic therapy
• Must have normal organ function
• Must have the ability to understand and willingness to sign a written informed consent form

You may not qualify if…

• No other agents or therapies administered with the intent to treat malignancy
• Patients with prior exposure to obatoclax
• Uncontrolled, intercurrent illness
• Pregnant women and women who are breast feeding

Where it is running

• NW Georgia Oncology Centers — Marietta, Georgia, United States
• Northwestern University Feinberg School of Medicine — Chicago, Illinois, United States
• Hackensack University Medical Center — Hackensack, New Jersey, United States
• Roswell Park Medical Center — Buffalo, New York, United States
• University of Wisconsin — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.